Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02230202 · ClinicalTrials.gov registry record

Endothelial Microparticles: A Novel Marker of Vascular Dysfunction

A clinical trial of Chronic Kidney Disease, sponsored by University of Colorado, Denver.

Completed
Registry status
90
Enrollment target
2
Study locations

NCT02230202 is a study of Chronic Kidney Disease that has completed, run by University of Colorado, Denver. The registered enrollment target is 90 participants, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02230202, a study of Chronic Kidney Disease, has completed, sponsored by University of Colorado, Denver.

COMPLETED
Registry status
90 participants
Enrollment target
2
Study locations

Study Summary

The primary hypothesis of this proposal is that chronic kidney disease (CKD) and treatment with calcineurin inhibitors (CNIs) are each associated with the release of endothelial microparticles into the plasma.

Conditions Studied

Interventions

  • OTHER Flow-mediated dilation
  • OTHER single blood draw

Study Locations (2)

Colorado

  • University of Colorado Anschutz Medical Campus; CTRC - Aurora
  • University of Colorado School of Medicine - Aurora

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2014-09
Est. Completion 2016-03

Sponsor

University of Colorado, Denver

1,283 total trials

What the Registry Record Tells You About NCT02230202

The ClinicalTrials.gov registry entry for NCT02230202 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (97% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Flow-mediated dilation is the first listed.

NCT02230202 reports 2 study locations spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT02230202 about?

NCT02230202 is a clinical study titled "Endothelial Microparticles: A Novel Marker of Vascular Dysfunction". The primary hypothesis of this proposal is that chronic kidney disease (CKD) and treatment with calcineurin inhibitors (CNIs) are each associated with the release of endothelial microparticles into the plasma.

What is the current status of trial NCT02230202?

This trial is currently completed. The enrollment target is 90 participants. The study started on 2014-09. Estimated completion is 2016-03.

What conditions does trial NCT02230202 study?

This clinical trial studies the following conditions: Chronic Kidney Disease.

What interventions are being tested in trial NCT02230202?

The interventions under investigation include: Flow-mediated dilation (OTHER), single blood draw (OTHER).

Who is sponsoring clinical trial NCT02230202?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02230202 being conducted?

This trial has 2 study locations across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Kidney Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.